Key points are not available for this paper at this time.
CCR expression does not diminish CAR T-cell antitumor activity. A, Schematic of the xenograft model. On day 0, NSG mice were injected via tail vein with 1 × 106 CD123+ MV-4-11.ffLuc cells. In treatment groups, 2 × 106 T cells were administered on day 7. Cohorts: unmodified (NT), CD28.ζ CAR, and CD28.ζ CAR + IL7Rα CCR-T cells. B, Leukemia proliferation was monitored with BLI, and whole-animal radiance was recorded (photons/second/cm2/sr). Comparison of radiance in each group was performed following log transformation of each measured value. C, Kaplan–Meier survival analysis of MV-4-11 xenografts (n = 9 mice per condition; two independent experiments; median survival: NT: 45.5 days; CAR: 93.5 days; CAR + CCR: undefined; ***, P P
Vorri et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: